Printer Friendly

Transitional cell carcinoma of fallopian tube: a case report.

INTRODUCTION: Primary fallopian tube cancer is a rare malignancy. It is commonly confused clinically with ovarian mass. The commonest clinical features are clear or blood stained discharge per vaginum and abdominal pain. As the fallopian tube distends with the mass, the patient has severe abdominal pain and thus presents earlier to the clinician. However thorough clinical examination may still not enable a preoperative diagnosis and thus intra-operative inspection becomes very important to label it as of primary tubal origin. The management is similar to epithelial ovarian cancer. It carries a better prognosis than ovarian tumours as it tends to be diagnosed early and has a better five year survival rate.

CASE SUMMARY: A 68 year old para 4 was admitted from the Gynecology outpatient department, Dr. R. P. G. M. C. Tanda, Distt. Kangra, H. P., with the chief complaint of Postmenopausal bleeding for 22 days. Bleeding was dark red, scanty, soaking one pad per day and not responding to medications.

No complaint of discharge per vaginum.

No urinary or bowel complaint.

She had attained Menopause 16 years back. She was parafour with all full term vaginal deliveries. There was no history of any other major illness and her personal history & family history was not significant. Patient gave history of similar complaints 12 years back but was not investigated then. No complaint since then.

INVESTIGATIONS: ULTRASOUND: Uterus small, atrophic, 58x41x19 mm. in size. Appears to be normal. The evidence of hypoechoic area 22 x 6 mm in upper endometrial cavity suggestive of? polyp? Endometrial thickening:

Bilateral adenexa normal.


Scanty curettings obtained.

On HPE, Autolytic changes with few inflammatory changes seen. (Inconclusive)

In view of two episodes of postmenopausal bleeding and USG suggestion of? polyp? Endometrial thickening, she was posted for total abdominal hysterectomy and bilateral salpingooopherectomy.


* Uterus small menopausal size.

* Left fallopian tube showing hematosalpinx of 5x2 cms.

* Left ovary normal.

* Right tube and ovary normal.

* Peritoneal surfaces normal.

* Omentum normal looking.

* No free fluid in pelvis.


* Specimen- uterus 6x 3.5x2cms in size.

* Left Fallopian tube dilated and measured 1.5 cm in diameter and 9 cm in length.

* Cut section- lumen filled with grey white tumour.


TRANSITIONAL CELL CARCINOMA: Muscularis was attenuated, no invasion into muscularis. Tumor composed of cells with coffee-bean like nuclei arranged in solid nests without keratinization suggestive of transitional cell histology.

Ovary and contralateral adenexa along with endometrium and cervix were free of tumour. Patient received six cycles of Cisplatin based chemotherapy three weekly. At present she has no complaints and is under surveillance.

DISCUSSION: Incidence of fallopian tube carcinoma is 0.5% of all gynaecological malignancies. (1) Largest series was of 3051 cases by Stewart et al. (2)

* 88%--adenocarcinoma.

* 89%--unilateral.

* Rare varieties--leiomyosarcoma, transitional cell carcinoma.

Latzko triad (15%). (3-4)

* Intermittent watery discharge (hydrops tubal profulens).

* Colicky abdominal/pelvic pain.

* Abdominal/ pelvic mass.

Primary fallopian tube carcinoma (PFTC), first described by Renaud in 1847, is the least common gynecological malignancy encountered in practice. Though histologically and clinically, fallopian tube carcinoma resembles epithelial ovarian cancer (EOC), transitional cell carcinoma of the fallopian tube is a very rare histological variant, with only around 20 cases having been reported worldwide so far. (5-6)

CA-125 is also found to be a good marker for post-treatment follow-up, similar to ovarian carcinoma. (7) Optimally cytoreduced patients with primary fallopian tube carcinoma treated with a paclitaxel-based chemotherapy regimen have an excellent possibility of survival. (8)


Stage I: Tumor limited to one or both tubes, with or without ascites.

Stage II: Tumor involves one or both tubes with pelvic extension and/or metastasis to the uterus or ovary or extension to other pelvic tissues.

Stage III: Tumor involves one or both tubes with peritoneal implants outside the pelvis and/or regional nodes.

Stage IV: Distant metastasis outside the peritoneal cavity.


* Same as that of epithelial ovarian cancers, i.e.,

* Exploratory laparotomy to remove the primary disease + staging and debulking.

* Cisplatin and Paclitaxel based chemotherapy.

* 5 year survival rates of 40% are better than ovarian cancers.

DOI: 10.14260/jemds/2015/1217


(1.) Fallopian tube carcinoma: A review. Pectasides D, Pectasides E, Economopoulos T, Oncologist. 2006 Sep; 11 (8): 902-12.

(2.) The incidence of primary fallopian tube cancer in the United States. Stewart SL, Wike JM, Foster SL, Michaud F. Gynecol Oncol. 2007 Dec; 107 (3): 392-7. Epub 2007 Oct. 24.

(3.) Callahon TL, Caughey AB, Blueprinys obs. & gyne. Lippincott Williams & wilkins (2008) ISBN: 078178249.

(4.) Gibbs RS, Danforth DN, Karlon BY et al. Danforth's obs. & gynecology Lippincott W@illiams & Wilkins (2008) ISBN: 078176937.

(5.) Gupta N, Srinivasan R, Nijhawan R, Dhaliwal LK. Primary fallopian tube carcinoma with exfoliation of malignant cells in cervical Pap smear. Cytojournal. 2005; 2: 20. [PMC free article] [PubMed].

(6.) Chin H, Matsui H, Mitsuhashi A, Nagao K, Sekiya S. Primary transitional cell carcinoma of the fallopian tube: A case report and review of literature. Gynecol Oncol. 1998; 71: 469-75. [PubMed].

(7.) Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: A review. Oncologist. 2006; 11: 902-12. [PubMed].

(8.) Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gemignani ML1, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR. GynecolOncol. 2001 Jan; 80 (1): 16-20.

Anju Vij [1], Neelam Mahajan [2], Amit Gupta [3], Rajinder Kumar [4], Renu Sharma [5]


[1.] Anju Vij

[2.] Neelam Mahajan

[3.] Amit Gupta

[4.] Rajinder Kumar

[5.] Renu Sharma


[1.] Associate Professor, Department of Obstetrics & Gynaecology, DRPGMC, Tanda, Kangra District, H. P.

[2.] Professor, Department of Obstetrics & Gynaecology, DRPGMC, Tanda, Kangra District, H. P.

[3.] Associate Professor, Department of Obstetrics & Gynaecology, DRPGMC, Tanda, Kangra District, H. P.

[4.] Professor, Department of Obstetrics & Gynaecology, DRPGMC, Tanda, Kangra District, H. P.

[5.] Assistant Professor, Department of Obstetrics & Gynaecology, DRPGMC, Tanda, Kangra District, H. P.



Dr. Anju Vij, Department of Obstetrics & Gynaecology, DRPGMC, Tanda, Kangra District, H. P.


Date of Submission: 12/05/2015.

Date of Peer Review: 13/05/2015.

Date of Acceptance: 06/06/2015.

Date of Publishing: 15/06/2015.
COPYRIGHT 2015 Akshantala Enterprises Private Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CASE REPORT
Author:Vij, Anju; Mahajan, Neelam; Gupta, Amit; Kumar, Rajinder; Sharma, Renu
Publication:Journal of Evolution of Medical and Dental Sciences
Date:Jun 15, 2015
Previous Article:Risk factors for development of lymphedema following breast cancer treatment: a retrospective study.
Next Article:Suture material-it's importance in wound healing.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters